Abingdon Health Plc (ABDXF) Research

Abingdon Health Plc is a global enterprise dedicated to the innovation, production, and worldwide distribution of diagnostic technologies. Their diverse product portfolio includes rapid self-diagnostic tools like the AbC-19 Rapid Test for detecting COVID-19 IgG antibodies and the 2019-nCoV Antigen Test for identifying SARS-CoV-2 antigens. They also offer a range of nucleic acid lateral flow immunoassays, including the PCRD and PCRD FLEX systems, which provide quick readouts following isothermal amplification. The 'Abingdon Simply Test' line further expands their selection of consumer-friendly self-tests. Beyond physical tests, Abingdon Health provides AppDx, an innovative, customizable image-capturing technology that essentially transforms any smartphone into a self-contained lateral flow reader. The company also extends its expertise through a variety of services, including contract manufacturing, bespoke nucleic acid lateral flow test customization, and comprehensive lateral flow development and production. Additionally, they offer strategic consultancy to businesses operating within the healthcare technology sector. Notably, Abingdon Health Plc maintains a significant collaboration and co-marketing agreement with Abcam plc. Founded in 2008, the company's operations are centrally managed from its headquarters in York, United Kingdom.

Open Abingdon Health Plc (ABDXF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.